All In Biotech

Drug Trial Radar · NCT06842992

A Phase II Study to Evaluate NH102 for Depression

A Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Dose-exploration Phase II Clinical Trial to Evaluate the Efficacy and Safety of NH102 in the Treatment of Depression

Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 243 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

243

Actual

Start

Dec 4, 2024

Primary completion

Jul 30, 2025

Study completion Sep 12, 2025

Sponsor

Sponsor type
Industry
First posted
Feb 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, randomized, double-blind, double-dummy, parallel-group, dose-finding Phase II clinical trial with placebo and active comparator duloxetine . It is designed to preliminarily assess the efficacy and safety of NH102 in patients with major depressive disorder and to provide the basis for the design of Phase III clinical trials.

Conditions

  • Major Depressive Disorder (MDD)

Interventions

  • NH102Drug

    5 mg twice daily over 6 weeks, followed by a 1-week tapering period.

  • NH102Drug

    10 mg twice daily over 6 weeks, followed by a 1-week tapering period.

  • NH102Drug

    15 mg twice daily over 6 weeks, followed by a 1-week tapering period.

  • Duloxetine Hydrochloride Enteric-coated CapsuleDrug

    30 mg twice daily for 6 weeks, followed by a 1-week tapering period.

  • PlaceboDrug

    Matched dosing regimen.Twice daily for 6 weeks, followed by a 1-week tapering period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 17 items Hamilton Depression Scales (HAM-D17)Time frame: 6 Weeks

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Anhui Mental Health Center

    Hefei, Anhui, China

  • Beijing Huilongguan Hospital

    Beijing, Beijing Municipality, China

  • Chongqing Mental Health Center

    Chongqing, Chongqing Municipality, China

  • Xiamen Xianyue Hospital

    Xiamen, Fujian, China

  • The Affiliated Brain Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • Shenzhen Kangning Hospital

    Shenzhen, Guangdong, China

  • Hebei Mental Health Hospital

    Baoding, Hebei, China

  • The Second Affiliated Hospital of Henan Medical University

    Xinxiang, Henan, China

  • Zhumadian Second People's Hospital

    Zhumadian, Henan, China

  • Hunan Second people's Hospital

    Changsha, Hunan, China

  • Suzhou Guangji Hospital

    Suzhou, Jiangsu, China

  • Wuxi Mental Health Center

    Wuxi, Jiangsu, China

  • Nanchang Mental Health Center

    Nanchang, Jiangxi, China

  • Jilin Provincial Neuropsychiatric Hospital

    Siping, Jilin, China

  • Shongdong Mental Health Center

    Jinan, Shandong, China

  • Shanghai Mental Health Center

    Shanghai, Shanghai Municipality, China

  • Frist Hospital of Shanxi Medical University

    Taiyuan, Shanxi, China

  • Xi'an Mental Health Center

    Xi’an, Shanxi, China

  • The Fourth People's Hospital of Chengdu

    Chengdu, Sichuan, China

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China

  • Tianjin Anding Hospital

    Tianjin, Tianjin Municipality, China

  • Hangzhou Seventh People's Hospital

    Hangzhou, Zhejiang, China

  • Huzhou Third Municipal Hospital

    Huzhou, Zhejiang, China

  • The Affiliated Kangning Hospital of Ningbo University

    Ningbo, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.